Built with the best in class.
Portal has built a community of best-in-class partners across industries, developed over the course of years of shared experiences and successes. We value these relationships and leverage them to support each stage of growth for our portfolio companies.
Portal welcomes Grove Biopharma, an ambitious startup spun out of Northwestern University, as a new venture.
We are honored to have Walder Ventures as the founding sponsor of Portal Innovations. Our organizations share a bold vision to accelerate ambitious thinking in biomedical innovation and create a thriving ecosystem to support life science entrepreneurs.
Inspired by Joseph Walder’s lifelong passion for scientific discovery, Walder’s support helps us provide capital, infrastructure, and expertise to high-potential startups developing breakthrough products to help patients.
Cardiosense
Venture
Cardiosense is building a digital biomarker platform that leverages novel, multi-sensor devices and proprietary algorithms to detect early signs of disease and guide personalized therapy.
CiRC Biosciences
Venture
CiRC is a privately held, cell therapy company, developing treatments for serious diseases with high, unmet needs with an initial focus on the eye. Founded in 2019, CiRC is in pre-clinical development for the use of chemically induced retinal cells for vision restoration and specifically pursuing a treatment for Geographic Atrophy Age-Related Macular Degeneration (“Dry AMD”) and advanced Retinitis Pigmentosa (RP).
ClostraBio
Venture
ClostraBio is dedicated to creating new therapeutics to treat inflammatory bowel disease (IBD) and food allergy.
Dimension Inx.
Venture
Dimension Inx. designs and develops therapeutic products that restore tissue and organ function. Their biomaterials and manufacturing process enables unparalleled design versatility and a nuanced microarchitecture that drives biofunctionality.
Grove Biopharma
Venture
A revolutionary platform biotech company, Grove Biopharma operates at the intersection of materials science and medicinal chemistry. Based on the work from the lab of Northwestern University Professor Nathan Gianneschi, Grove focuses on the discovery and development of a new class of biotherapeutics to treat significant unmet medical needs in chronic inflammatory and neurodegenerative diseases.
Inomagen Therapeutics
Venture
Inomagen Therapeutics is a private, preclinical stage biotechnology company developing a biological (gene) therapy to improve the treatment of atrial fibrillation.
ReAx Biotechnologies
Venture
ReAx is a Chicago-based, pre-clinical company that is applying next generation chemical proteomic platforms to discover, optimize and validate small molecules directly in cells.
Rhaeos
Venture
Arising from a collaboration between materials scientists and neurological surgeons at Northwestern University, Rhaeos has developed a noninvasive thermal sensor for use in the monitoring of ventricular shunt function. In this manner, they hope to eradicate the uncertainty faced by patients, families and healthcare providers alike.
Syntax Bio
Venture
Synthetic Biology company based in Chicago.
Zylem Biosciences
Venture
Zylem Biosciences is a startup biotechnology company developing targeted medicines based on its novel platform technology: A surface chemical mimic of natural high-density lipoprotein (HDL). Zylem has developed a deep pipeline of therapies applicable to diseases and conditions where lipid dysfunction plays a critical role.
Next
See our news
Get in touch
1375 West Fulton Street, Chicago, IL 60607
©2023 Portal Innovations, LLC